Mesa Laboratories Inc

Mesa Laboratories Inc(MLAB)股票分析

$126.160

-1.388 (-1.10%)收盘时

Loading chart…
最高
129.380
开盘
125.190
成交量加权均价
126.91
成交量
79.58K
市值
458.17M
最低
125.190
成交额
10.10M
企业价值/息税折旧摊销前利润(TTM)
14.41

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

AI 分析 of Mesa Laboratories Inc (MLAB)

持有

Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.

分析师评级(2)

-21.53% 下跌空间
买入
1 买入
1 持有
0 卖出
当前: 126.16
最低
83.00
平均
99.00
最高
115.00

Wells Fargo

2026-02-04

目标价

$94

Equal Weight

Wells Fargo

2025-12-15

目标价

$83

Equal Weight

Jefferies

2025-11-07

目标价

$115

买入

Wells Fargo

2025-08-07

目标价

$67

Equal Weight

Wells Fargo

2025-05-30

目标价

$100

减持

估值指标

Mesa Laboratories Inc(MLAB)当前预期市盈率为 34.48,5 年平均预期市盈率为 30.08。

预期市盈率

合理
5 年均值 P/E
30.08
当前P/E
34.48
高估
45.05
低估
15.12

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
18.74
当前EV/EBITDA
14.41
高估
28.36
低估
9.12

预期市销率

合理
5 年均值 P/S
3.28
当前P/S
2.65
高估
4.91
低估
1.65

Alphio AI 对 MLAB 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MLAB

$100.37

情景价格

基

基准

基准 · 50%MLAB

$97.94

情景价格

悲

悲观

悲观 · 25%MLAB

$84.63

情景价格

持有 MLAB 的大户

R

Ranger Investment Management, L.P.

+ 持有MLAB

-12.38%

3个月收益率

事件时间线

2026-10-13 (ET)

08:30:00

Mesa Labs Announces Savings Plan to Cut Annual Operating Costs by $9.3M

2026-08-10 (ET)

16:30:00

Mesa Q1 Revenue at $60.14M, Below Consensus

2026-05-27 (ET)

08:10:00

Mesa Q1 Revenue at $63.72M, Below Consensus

2026-03-09 (ET)

16:40:00

Mesa Labs Appoints Siddhartha Kadia as New CEO

2026-02-03 (ET)

08:10:00

Mesa Reports Q3 Revenue of $65.126M, Beating Consensus

资讯

MLAB 常见问题 —— 由 Alphio AI 解答

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.

2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易